Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies
Molecular Therapy: Oncology
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитирование
Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926001414?dgcid=rss_sd_all
Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926001414?dgcid=rss_sd_all
“Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies.” Molecular Therapy: Oncology.
@article{article119285,
title = {Next-generation LMP2A-targeting TCR-recombinant T cells with inducible IL-18 expression to treat EBV-associated malignancies},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926001414?dgcid=rss_sd_all}
}